A detailed history of Black Rock Inc. transactions in Immunome Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,758,864 shares of IMNM stock, worth $41.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,758,864
Previous 829,013 353.41%
Holding current value
$41.3 Million
Previous $20.5 Million 122.3%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.54 - $22.11 $33.8 Million - $64.8 Million
2,929,851 Added 353.41%
3,758,864 $45.5 Million
Q1 2024

May 10, 2024

BUY
$11.01 - $27.34 $4.83 Million - $12 Million
438,377 Added 112.22%
829,013 $20.5 Million
Q4 2023

Feb 13, 2024

BUY
$7.3 - $10.73 $2.54 Million - $3.74 Million
348,107 Added 818.52%
390,636 $4.18 Million
Q3 2023

Nov 13, 2023

SELL
$6.17 - $9.16 $4,831 - $7,172
-783 Reduced 1.81%
42,529 $355,000
Q2 2023

Aug 11, 2023

BUY
$4.7 - $7.91 $8,333 - $14,024
1,773 Added 4.27%
43,312 $342,000
Q1 2023

May 12, 2023

SELL
$3.26 - $5.69 $1,398 - $2,441
-429 Reduced 1.02%
41,539 $207,000
Q4 2022

Feb 13, 2023

BUY
$2.21 - $5.0 $1,140 - $2,580
516 Added 1.24%
41,968 $92,000
Q3 2022

Nov 14, 2022

BUY
$3.39 - $6.14 $7,596 - $13,759
2,241 Added 5.72%
41,452 $183,000
Q2 2022

Aug 12, 2022

SELL
$2.24 - $5.79 $799 - $2,067
-357 Reduced 0.9%
39,211 $126,000
Q1 2022

May 12, 2022

SELL
$3.88 - $13.99 $4,155 - $14,983
-1,071 Reduced 2.64%
39,568 $224,000
Q4 2021

Feb 10, 2022

BUY
$12.96 - $23.44 $1,697 - $3,070
131 Added 0.32%
40,639 $527,000
Q3 2021

Nov 09, 2021

BUY
$12.5 - $27.76 $220,275 - $489,186
17,622 Added 77.0%
40,508 $986,000
Q2 2021

Aug 11, 2021

BUY
$16.33 - $32.33 $373,728 - $739,904
22,886 New
22,886 $396,000

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $133M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.